OMB Clears FDA’s Final Guidance On Clinical Research For Cannabis

By Beth Wang / January 18, 2023 at 4:17 PM
The White House Office of Management and Budget has completed its review of FDA’s final guidance on clinical research for cannabis and cannabis-derived compounds, coming as the agency also reportedly plans to make recommendations for how to regulate cannabis-derived products, including those containing cannabidiol (CBD). The guidance cleared by OMB on Jan. 13, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research,” is focused on development of cannabis-based drug products. It also discusses key regulatory concepts for stakeholders who may...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.